End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.36 CNY | +0.41% | -5.60% | -27.02% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.02% | 479M | - | ||
+17.80% | 66.43B | A- | ||
+2.92% | 49.89B | A- | ||
+19.98% | 41.88B | B+ | ||
+20.88% | 26.48B | A- | ||
+12.04% | 19.68B | C+ | ||
+1.27% | 17B | B+ | ||
-22.98% | 16.12B | A- | ||
+2.77% | 15.28B | B+ | ||
-9.25% | 15.18B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301349 Stock
- Ratings Liaoning Xinde New Material Technology Co., Ltd.